Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LOAd703 plus Atezolizumab in Melanoma
NCT04123470Phase 2Completed
- Sponsor
- Lokon Pharma
- Start
- Jan 2020
- Primary completion
- Jul 2023
- Modality
- Gene Editing, Prophylactic Vaccines, Gene Silencing
- Countries
- 2
01
Overview
Phase 2, open-label, single-arm trial of delolimogene mupadenorepvec in Malignant Melanoma (MM), sponsored by Lokon Pharma. Primary endpoint: Tolerability Evaluated by NCI CTCAE v5.0 up to 57 weeks. Started Jan 2020; status: completed.
02
Drugs
delolimogene mupadenorepvec
03
Conditions
Malignant Melanoma (MM)
Beyond the preview
Go deeper on NCT04123470.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04123470.